Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Year: 2022
Type: article
Source: Blood
Authors: Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Institutions: Centre Hospitalier Universitaire de Toulouse, Université de Lille, Centre Hospitalier Universitaire de Lille, University of Southern Denmark, Vejle Sygehus, Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of Calgary, Hôpital Cardiologique du Haut-Lévêque, The University of Texas MD Anderson Cancer Center, Karolinska University Hospital, Karolinska Institutet, Princess Alexandra Hospital, Oxford University Hospitals NHS Trust, Centre Hospitalier Universitaire de Limoges, Universitair Ziekenhuis Leuven, Hospices Civils de Lyon, Hôpital Saint-Louis, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Janssen Scientific Affairs (United States), Janssen Research & Development (United States), University Medical Center Hamburg-Eppendorf
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310106426